Copper Tripeptide-1: INCI Identity, Evidence & Legal Status

"Copper Tripeptide-1" is the International Nomenclature of Cosmetic Ingredients (INCI) name for the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine — in other words, it is the cosmetic-grade label for the identical molecule the research literature calls GHK-Cu.45 On the cosmetics side its evidenced function is skin- and hair-conditioning, and the U.S. Cosmetic Ingredient Review (CIR) Expert Panel formally judged it safe as used in cosmetics at the low concentrations actually present in finished products.1 This monograph focuses on what is specific to the cosmetic listing — the regulatory identity, the safety review, topical penetration science, formulation rules, and the cosmetic-vs-drug line.

This article is informational and editorial content for educational purposes only. It is not medical advice, not a protocol, and not a sourcing or buying guide. Copper Tripeptide-1 is the cosmetic INCI name for GHK-Cu; a cosmetic ingredient listing does not make any injectable form approved or safe. Concentration and formulation figures are reported strictly as seen in the literature for completeness. People with Wilson's disease or other copper-handling disorders should avoid copper peptides. Consult a licensed clinician before any health decision.

What is Copper Tripeptide-1 and how does it relate to GHK-Cu?

Copper Tripeptide-1 is the INCI-assigned name for glycyl-L-histidyl-L-lysine:copper(II) — the same Gly-His-Lys:Cu complex documented under the research name GHK-Cu, and the same molecule whose injectable pharmaceutical salt is prezatide copper acetate.4 Cosmetic-trade data list molecular formula C14H22N6O4Cu, molecular weight about 340.4 g/mol, CAS 89030-95-5 for the peptide-copper complex (the apo-peptide GHK is CAS 49557-75-7), COSING reference 55687, and FDA UNII 6BJQ43T1I9; the raw material is a characteristic blue powder made synthetically for cosmetic use rather than extracted from human plasma.45 The COSING-listed cosmetic functions are skin conditioning and hair conditioning.5

The full mechanism of action — copper delivery to lysyl oxidase for collagen and elastin cross-linking, matrikine signaling to fibroblasts, biphasic matrix remodeling, broad gene-expression modulation, and antioxidant and anti-inflammatory action — is identical to and documented in the companion GHK-Cu monograph, because it is the same molecule. What matters for the cosmetic context is that this is a topical, local skin-signaling and copper-delivery mechanism. Notably, the cosmetics safety literature records that after intravenous injection the tripeptide is rapidly degraded by plasma aminopeptidases to L-histidyl-L-lysine and cleared within minutes — it is not systemically stable, reinforcing that the molecule's plausible cosmetic action is local and topical, not systemic.1

What is the evidence for Copper Tripeptide-1?

The substantive human-efficacy evidence for the molecule (topical anti-aging, diabetic-ulcer healing, hair) is graded and detailed in the GHK-Cu monograph. The table below states the cosmetic-relevant conclusions plus the penetration evidence that is unique to the INCI listing.

The cosmetic-distinctive evidence is the penetration work. In a controlled in-vitro study on excised human cadaver skin using Franz-type flow-through diffusion cells, the copper tripeptide permeated isolated stratum corneum readily but isolated viable epidermis very poorly: permeability coefficients ran about 55.9 x 10^-4 cm/h for stratum corneum versus roughly 0.003 x 10^-4 cm/h for isolated epidermis — an approximately 18,600-fold drop into viable skin. Copper accumulated about 438-fold over baseline in the stratum corneum, with only about 2% of dose reaching the receptor through full-thickness skin.2 You can read the full study via PubMed Central at PMC3016279. The interpretation is that the copper-tripeptide is good at loading copper into the outer barrier but limited at delivering it into living dermis without enhancement.

That makes "advanced delivery" claims worth scrutinizing. A 2025 review concluded there are no quantitative data showing liposomal encapsulation significantly outperforms free GHK-Cu for skin retention or permeation; one comparison found liposomal and free-form skin retention statistically indistinguishable, and the field's measurement methodology remains immature.3 So while marketing leans heavily on encapsulation, the delivery advantage is not yet evidenced.

How should Copper Tripeptide-1 be formulated and used?

Reported strictly as cosmetic-formulation practice, not a protocol. Cosmetic use is topical. Finished cosmetics typically formulate copper-tripeptide-1 at 0.05-1% of the product, with higher levels flagged as more likely to irritate; notably, the CIR safety review found that actual reported in-product use concentrations were under 10 ppm (about 0.001%) — far less than the nominal 1% ceiling.61 Application is usually once or twice daily in leave-on serums, creams, or eye creams, with evening use commonly recommended so it is not layered immediately with morning vitamin C.7

Formulation chemistry is decisive. The copper-peptide chelation bond is most stable at pH 5.0-7.0 (best around 5.5-6.5); outside that window the complex destabilizes and loses activity.6 Pure L-ascorbic acid can strip copper from the peptide via low pH and redox interaction, so vitamin C and copper peptides are typically separated to different times of day; strong chelators such as EDTA compete for the copper and inactivate the complex; and oxidizers or air exposure degrade the oxidation-sensitive complex, which is why air-restrictive packaging is used.76 Retinol and strong acids are best not layered immediately. Hyaluronic acid, ceramides, niacinamide, and gentle hydrators are generally treated as compatible.8

What is the safety and legal status of Copper Tripeptide-1?

For topical cosmetic use the safety verdict is favorable. The CIR Expert Panel assessed Tripeptide-1, Hexapeptide-12, their metal salts (which include Copper Tripeptide-1) and related derivatives and concluded they are safe as used in cosmetics, noting that the low use concentrations and negative safety-test data obviate concern.1 In the EU it is not listed in Annexes II-VI of Regulation (EC) 1223/2009 — not prohibited or restricted — though every finished product still requires its own safety assessment.5 Reported topical adverse events are mild and transient: irritation in a minority (more likely at higher concentrations or on a compromised barrier), rare copper contact allergy (a patch test is advisable), and an unwanted hair-growth effect on facial products.4 Copper-overload and zinc-balance concerns are systemic-dosing considerations that are not meaningfully engaged by a leave-on cosmetic delivering microgram quantities mostly into the stratum corneum. People with Wilson's disease or other copper-handling disorders should still avoid copper peptides as a precaution.2

The legal snapshot is simple but easy to get wrong. As a cosmetic ingredient, Copper Tripeptide-1 is sold OTC and is not FDA pre-approved; legality turns entirely on intended use and claims.9 Under the FD&C Act a product is a cosmetic if intended to beautify or alter appearance and a drug if intended to affect the structure or function of the body — so a Copper Tripeptide-1 product is a legal cosmetic only while its claims stay appearance-based, and claims like "stimulates collagen production" or "reverses aging" reclassify it as an unapproved new drug, a violation the FDA routinely flags.10 Permitted in EU cosmetics as well, with therapeutic claims triggering medicines law just as in the U.S.5 It is not named on the WADA Prohibited List, so topical cosmetic use is a non-issue for athletes.9

Bottom line. Copper Tripeptide-1 is the cosmetic INCI name for GHK-Cu — judged safe as used in cosmetics by the CIR Panel, with a genuine but modest Grade B topical anti-aging signal and Grade C hair benefit. The cosmetic-distinctive science is about delivery: it loads copper into the stratum corneum but crosses poorly into viable skin, and the touted liposomal advantage is not proven, so formulation quality matters as much as the ingredient. The single most important take-away on legality: the same molecule is a legal cosmetic with appearance claims and an unapproved drug the instant the label promises collagen-building effects — and a cosmetic listing confers no legitimacy on injectable GHK-Cu, which is a separate, unapproved drug substance.9 Regulatory facts here are current as of June 2026 and should be re-verified for later developments.